NZ593613A - Intranasal desmopressin administration - Google Patents

Intranasal desmopressin administration

Info

Publication number
NZ593613A
NZ593613A NZ593613A NZ59361309A NZ593613A NZ 593613 A NZ593613 A NZ 593613A NZ 593613 A NZ593613 A NZ 593613A NZ 59361309 A NZ59361309 A NZ 59361309A NZ 593613 A NZ593613 A NZ 593613A
Authority
NZ
New Zealand
Prior art keywords
desmopressin
dispensers
safe
intranasal
desmopressin administration
Prior art date
Application number
NZ593613A
Other languages
English (en)
Inventor
Seymour Fein
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42168193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ593613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NZ593613A publication Critical patent/NZ593613A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A61M15/085—Fixing means therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
NZ593613A 2008-12-22 2009-12-21 Intranasal desmopressin administration NZ593613A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13987108P 2008-12-22 2008-12-22
PCT/US2009/068962 WO2010075266A2 (en) 2008-12-22 2009-12-21 Safe desmopressin administration

Publications (1)

Publication Number Publication Date
NZ593613A true NZ593613A (en) 2013-02-22

Family

ID=42168193

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ593613A NZ593613A (en) 2008-12-22 2009-12-21 Intranasal desmopressin administration

Country Status (19)

Country Link
US (4) US20120015880A1 (cg-RX-API-DMAC7.html)
EP (2) EP2381923B2 (cg-RX-API-DMAC7.html)
JP (4) JP5731396B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170081711A (cg-RX-API-DMAC7.html)
CN (2) CN105963834A (cg-RX-API-DMAC7.html)
AU (1) AU2009330203B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923557A2 (cg-RX-API-DMAC7.html)
CA (1) CA2747998C (cg-RX-API-DMAC7.html)
DK (1) DK2381923T4 (cg-RX-API-DMAC7.html)
EA (2) EA201791732A1 (cg-RX-API-DMAC7.html)
ES (1) ES2692345T5 (cg-RX-API-DMAC7.html)
IL (1) IL213699A (cg-RX-API-DMAC7.html)
MX (1) MX2011006765A (cg-RX-API-DMAC7.html)
NZ (1) NZ593613A (cg-RX-API-DMAC7.html)
PL (1) PL2381923T5 (cg-RX-API-DMAC7.html)
PT (1) PT2381923T (cg-RX-API-DMAC7.html)
SG (2) SG10201509152VA (cg-RX-API-DMAC7.html)
WO (1) WO2010075266A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105420B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021007A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
SG10201509152VA (en) * 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
CA2765221C (en) * 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration
EP3024473A1 (en) 2013-07-23 2016-06-01 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
CN105579057A (zh) * 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
CA2967390A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS171787B1 (cg-RX-API-DMAC7.html) 1973-11-09 1976-11-29
US4148787A (en) 1976-05-24 1979-04-10 Ferring Ab Antidiuretically effective polypeptide and a process for preparing the same
US4771769A (en) 1982-12-20 1988-09-20 Schering Corporation Hand held metered spray dispenser
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US4944429A (en) 1987-08-28 1990-07-31 Schering Corporation Manually-operable spray dispenser with locking mechanism
US5154122A (en) 1989-10-20 1992-10-13 Sol Goldschmidt Shipping device for suspended piece goods
CN1060980A (zh) * 1990-10-26 1992-05-13 蔡东林 多用电控自控微型喷雾器
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DK0708657T3 (da) * 1993-06-29 2001-10-15 Ferring Bv Sammensætninger til nasal administration af desmopression
WO1996040332A1 (en) * 1995-06-07 1996-12-19 O'neil, Christine Patient controlled drug delivery device
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
AU3421600A (en) 1999-02-14 2000-08-29 Ing. Erich Pfeiffer Gmbh Dispenser for flowable media
DE19938798A1 (de) 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
DE10110742A1 (de) 2001-02-28 2002-09-05 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
PL200833B1 (pl) 2001-09-21 2009-02-27 Pfeiffer Erich Gmbh & Co Kg Dozownik z pojemnikiem aplikowanego środka oraz pompka do dozownika
US20030232078A1 (en) 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2005046707A1 (en) * 2003-11-10 2005-05-26 Fein Seymour H Pharmaceutical compositions including low dosages of desmopressin
JP2007513199A (ja) * 2003-12-08 2007-05-24 ベントレー ファーマスーティカルス,インコーポレイテッド インスリン治療のための薬学的組成物及び方法
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
CN1785448A (zh) * 2005-11-11 2006-06-14 广东工业大学 医用防染式药雾吸入喷嘴
EP2035031A4 (en) * 2006-06-08 2010-02-24 Cpex Pharmaceuticals Inc INSULIN COMPOSITION
SG10201509152VA (en) * 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
CA2765221C (en) 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration

Also Published As

Publication number Publication date
JP2015127350A (ja) 2015-07-09
KR101755042B1 (ko) 2017-07-06
EA201170873A1 (ru) 2012-02-28
JP5959076B2 (ja) 2016-08-02
JP5731396B2 (ja) 2015-06-10
EA201791732A1 (ru) 2018-03-30
JP2012513403A (ja) 2012-06-14
AU2009330203A1 (en) 2011-07-14
IL213699A (en) 2016-05-31
DK2381923T4 (da) 2023-09-11
ZA201105420B (en) 2012-04-25
JP2016196488A (ja) 2016-11-24
CA2747998C (en) 2016-05-31
CN105963834A (zh) 2016-09-28
EA028531B1 (ru) 2017-11-30
CN102355888A (zh) 2012-02-15
EP2381923A2 (en) 2011-11-02
JP6389209B2 (ja) 2018-09-12
SG10201509152VA (en) 2015-12-30
PL2381923T3 (pl) 2019-04-30
ES2692345T3 (es) 2018-12-03
MX2011006765A (es) 2011-11-01
KR20170081711A (ko) 2017-07-12
JP2018184407A (ja) 2018-11-22
PL2381923T5 (pl) 2024-08-26
EP2381923B2 (en) 2023-06-07
CA2747998A1 (en) 2010-07-01
EP2381923B1 (en) 2018-08-01
US20200078542A1 (en) 2020-03-12
SG172344A1 (en) 2011-07-28
ES2692345T5 (es) 2024-01-26
US20120015880A1 (en) 2012-01-19
WO2010075266A3 (en) 2011-01-06
KR20110102915A (ko) 2011-09-19
BRPI0923557A2 (pt) 2016-01-26
IL213699A0 (en) 2011-07-31
WO2010075266A2 (en) 2010-07-01
US20240342407A1 (en) 2024-10-17
AU2009330203B2 (en) 2015-09-03
DK2381923T3 (en) 2018-11-19
EP3437633A1 (en) 2019-02-06
US20220126039A1 (en) 2022-04-28
PT2381923T (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
MX2012000066A (es) Administracion segura de desmopresina.
WO2010075266A3 (en) Intranasal desmopressin administration
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
NZ701038A (en) Treating acute decompensated heart failure with relaxin
SG10201401823RA (en) Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
WO2011020064A3 (en) Low-profile intraluminal light delivery system and methods of using the same
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
WO2010033188A3 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
NZ593653A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
PH12014501629A1 (en) Treatment of cognitive disorders with (r)-7- chloro -n- (quinuclidin -3-yl) benzo[b] thiophene -2- carboxamide and pharmaceutically acceptable salts thereof
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MY150599A (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
WO2011061554A3 (en) Pharmaceutical composition for the treatment of bladder disorders
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
CN102380167B (zh) 口腔溃疡护理治疗仪
WO2011156715A3 (en) Methods of treating metabolic disorders and cardiovascular diseases
WO2011008490A3 (en) Combination therapies for the treatment of obesity
CN103751732A (zh) 一种治疗咳嗽的处方

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ALLERGAN, US

Free format text: OLD OWNER(S): SERENITY PHARMACEUTICALS CORPORATION

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20131227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161201

ASS Change of ownership

Owner name: SERENITY PHARMACEUTICALS LLC, US

Effective date: 20170811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2023 BY COMPUTER PACKAGES INC

Effective date: 20221130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2024 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2025 BY CLARIVATE IP SERVICES

Effective date: 20241209